FDG PET与心脏MRI在心脏结节病诊断及免疫抑制治疗监测中的价值
本研究为回顾性观察性研究,纳入31例经证实有心脏外结节病且疑诊心脏结节病的患者,比较FDG PET/CT与心脏MRI在诊断和管理中的贡献。结果显示,17例后续接受治疗的患者在首次检查时可见显著心肌FDG摄取(SUVmax>3.6),治疗后心肌SUVmax从6.5降至4.0(P<.01),心脏代谢体积从42.5降至4.1(P<.001),LVEF从45.8%升至50.9%(P<.031),而晚期钆增强体积无变化;未治疗患者所有参数均无变化。
要点
- 心肌FDG摄取(SUVmax>3.6)提示活动性炎症,治疗后SUVmax及心脏代谢体积显著下降。
- 心脏代谢体积可作为评估治疗反应的客观定量指标。
- 晚期钆增强体积在治疗前后无变化,未治疗患者FDG PET及心脏MRI参数均无变化。
关键影像表现/征象
- 首次检查时,22例后续接受治疗的患者中有17例显示显著心肌FDG摄取(心肌SUVmax>3.6)。
- 随访时心肌SUVmax从6.5降至4.0(P<.01),FDG高摄取肺及纵隔淋巴结病变也显著减少。
- 以阈值SUV定义的心肌体积(心脏代谢体积)均值从42.5降至4.1(P<.001)。
- 左心室射血分数(LVEF)从45.8%升高至50.9%(P<.031)。
- 晚期钆增强体积在治疗时无变化;未治疗患者任何FDG PET或心脏MRI参数均无变化。
诊断标准与关键数值
- 心肌FDG摄取显著定义为心肌SUVmax>3.6(用于首次检查时识别后续治疗患者)。
- 心脏代谢体积为高于阈值SUV的心肌体积定量指标,治疗后均值从42.5降至4.1(P<.001)。
临床应用与阅片要点
- 对疑诊心脏结节病患者,可结合FDG PET/CT与心脏MRI评估活动性炎症及治疗反应。
- 心肌SUVmax>3.6及心脏代谢体积可用于客观定量监测治疗反应。
- 晚期钆增强体积在治疗后无变化,解读时应结合FDG PET代谢指标。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To compare the contributions of cardiac MRI and PET in the diagnosis and management of cardiac sarcoidosis (CS), with particular reference to quantitative measures.
MATERIALS AND METHODS: This is a retrospective, observational study of 31 patients (mean age, 45.7 years) with proven extracardiac sarcoidosis and possible CS who were investigated with fluorine 18 fluorodeoxyglucose (FDG) PET/CT and cardiac MRI. Patients were treated at physicians' discretion with repeat combined imaging after an interval of 102-770 days (median, 228 days).
RESULTS: Significant myocardial FDG uptake was shown on visit 1 (myocardial maximum standardized uptake value [SUVmax] > 3.6) in 17 of 22 patients who were subsequently treated. Myocardial SUVmax decreased at follow-up (6.5 to 4.0; P < .01) and was matched by significant decreases in FDG-avid lung and mediastinal node disease. A volumetric measure of myocardium above a threshold SUV (cardiac metabolic volume) decreased from a mean of 42.5 to a mean of 4.1 (P < .001). This was associated with significant improvement in the left ventricular ejection fraction (LVEF) (45.8 increasing to 50.9; P < .031). There was no change in volume of late gadolinium enhancement at treatment. Patients who were untreated showed no change in any FDG PET or cardiac MRI parameter.
CONCLUSION: Myocardial FDG uptake in patients suspected of having CS is presumed to represent active inflammation. When treated with corticosteroids, this resolved or regressed at follow-up, with an improvement in LVEF and FDG-avid thoracic disease. Patients who were untreated showed no change in any parameter. Quantification of FDG-avid myocardium using cardiac metabolic volume is proposed as a useful objective measure for assessing response to therapy.© RSNA, 2020See also commentary by Gutberlet in this issue.
引用
- Coulden RA, Sonnex EP, Abele JT, et al. Utility of FDG PET and Cardiac MRI in Diagnosis and Monitoring of Immunosuppressive Treatment in Cardiac Sarcoidosis. Radiol Cardiothorac Imaging. 2020. PMID: 33778595. doi:10.1148/ryct.2020190140
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。